Theriva Biologics Secures $7.5 Million in Public Offering to Advance Cancer Therapies
Theriva Biologics Inc. has successfully closed a $7.5 million public offering to advance its pipeline of cancer therapies, following promising results from its VIRAGE Phase 2b clinical trial.
2 minutes to read